Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Horizon Kinetics Holding Corp reported a net loss attributable to the company of $18.35 million for the third quarter of 2026, compared to a net income of $7.24 million in the prior year period. Total revenue remained relatively flat at $18.03 million, but the bottom line was significantly impacted by investment losses within consolidated investment products and unrealized losses on investments.
ProKidney Corp. reported a net loss available to Class A common stockholders of $84.1 million for the nine months ended September 30, 2026, compared to $49.8 million in the prior year period. The increase in loss was primarily driven by higher research and development expenses, which rose to $110.8 million as the company continues its clinical programs.
Energous Corporation reported Q3 2026 revenue of $3.4 million, a 167% increase year-over-year, driven by commercial adoption of its wireless power technology. Year-to-date revenue of $9.6 million has already surpassed the company's total revenue for the full year 2025. The company reported a GAAP net loss of $2.5 million for the quarter while noting significant improvements in gross margin as production scales.
Term
Q3 2026
“Our third quarter results reflect continued momentum in the commercial adoption of Energous’ technology, with revenue growing significantly year over year and our year-to-date revenue performance already surpassing full-year 2025.”
Mallorie Burak, CEO and CFO of Energous
“We also made meaningful progress in improving gross margins as we continue to scale production to better support customer demand. Looking ahead, we see significant opportunity to build on this momentum as enterprises increasingly recognize the value of continuous, real-time visibility into their operations.”
Atrium Therapeutics reported third quarter 2026 financial results, highlighting the dosing of the first patient in its Phase 1/2 clinical trial for ATR 1072. The company also closed a $50 million private placement, extending its cash runway through 2028 with a pro-forma cash balance of $293.6 million.
Term
Q3 2026
“The last eight months have marked many firsts for Atrium, building toward our transition to a clinical stage company with the initiation of Corventis, the first clinical trial ever to target the root cause of PRKAG2 syndrome.”
Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics
“Our $50 million private placement with leading institutional investors extends our cash runway through 2028. With ~$290 million on our balance sheet, we are well positioned to deliver on our upcoming milestones.”
Brendan Winslow, Chief Financial Officer of Atrium Therapeutics
Blackstone Private Real Estate Credit and Income Fund reported total assets of $2.57 billion as of September 30, 2026, a significant increase from $1.58 billion at year-end 2025. Net investment income for the nine months ended September 30, 2026, was $65.3 million, driven by interest income from its growing portfolio of senior loans and debt securities.
ADARx Pharmaceuticals reported a significant increase in cash and cash equivalents to $570.6 million as of September 30, 2026, following its initial public offering and concurrent private placement. The company is advancing a clinical pipeline including onvuzosiran (Phase 3) and agazisiran (Phase 2), supported by a major collaboration with AbbVie that contributed to $326.4 million in total deferred revenue.
Once Upon a Farm, PBC reported net sales of $247.2 million for the nine months ended September 30, 2026, a significant increase from $176.7 million in the prior year period. Despite the revenue growth, the company incurred a net loss of $24.6 million for the first nine months of 2026, though this was an improvement over the $39.8 million net loss reported for the same period in 2025.
As of September 30, 2026, SKYX Platforms Corp. reported a significant increase in cash and cash equivalents to $19.4 million, up from $8.1 million at the end of 2025. Total assets grew to $63.3 million, while total liabilities decreased to $49.3 million, primarily driven by reductions in operating lease liabilities and convertible notes.
Vylor Inc. (formerly the Seed Business of Corteva) became an independent public company on October 1, 2026, following a tax-free spin-off. For the nine months ended September 30, 2026, the company reported net sales of $13,742 million and net income attributable to the company of $1,311 million, compared to $13,491 million and $1,646 million respectively in the prior year period.
AmpliTech Group reported Q3 2026 revenue of $6.58 million, an 8.0% increase year-over-year, driven by strong growth in its Spectrum Semiconductor Materials distribution business. The company narrowed its net loss sequentially to $1.89 million and reported a significant backlog surpassing $52 million as of October 2026.
VolitionRx reported financial results for the third quarter of 2026, highlighting progress in its Nu.Q platform across sepsis, lung cancer, and veterinary diagnostics. The company noted the launch of the French government-funded DETECSEPS program and active licensing discussions for its Capture-Seq technology in the liquid biopsy market.
Term
Q3 2026
“It has been a very full quarter as we have continued to execute our plan to commercialize our game-changing Nu.Q® platform. We have made strong progress across our key product pillars this year, evidencing clinical utility across a broad spectrum of indications whilst driving commercialization and licensing efforts worldwide. At the same time, we have taken decisive action to strengthen our financial profile by cutting costs and significantly reducing convertible note debt.”
Cameron Reynolds, President and Group Chief Executive Officer
Tenon Medical reported third quarter 2026 revenue of $1.4 million, a 22% increase year-over-year, driven by the commercial launch of its 3D-printed lateral screw for the SImmetry+ system. The company strengthened its balance sheet by raising $15.6 million in gross proceeds, repaying $5.12 million in convertible notes, and ending the quarter with $8.3 million in cash.
Vyome Holdings reported a net loss of $2.64 million for the nine months ended September 30, 2026, a significant improvement from the $9.20 million loss in the prior year period which was impacted by high transactional fees. The company strengthened its cash position to $6.96 million through ATM financing activities, while research and development expenses increased substantially to $1.58 million.
GCT Semiconductor reported Q3 2026 financial results with revenue increasing 148.6% year-over-year to $1.1 million. The company highlighted that year-to-date 5G chipset shipments exceeded 11,300 units and expanded its addressable market into terrestrial-based location services.
Term
Q3 2026
“We continued to make progress across our 5G customer programs in the third quarter, advancing integration and certification work with existing customers while expanding the range of applications our 5G chipsets can serve.”
Assembly Biosciences, Inc. is a non-accelerated filer and smaller reporting company focused on therapeutic product candidates, primarily through a collaboration with Gilead Sciences. As of September 30, 2026, the company remains pre-revenue and unprofitable, relying on third-party CROs and collaborators for clinical development and manufacturing.
Rocket Pharmaceuticals reported third quarter 2026 financial results, highlighting FDA alignment on the pivotal Phase 2 trial for RP-A501 in Danon disease with dosing completion expected by mid-2027. The company ended the quarter with $279.4 million in cash and investments, which is expected to fund operations into the third quarter of 2028.
Term
Q3 2026
“With FDA alignment on the pivotal RP-A501 trial in Danon disease, our priority is to complete dosing by mid-2027. We are also advancing our broader cardiovascular portfolio, with dosing initiated in the Phase 1 trial of RP-A701 for BAG3-DCM and continued FDA engagement on a potential pivotal study of RP-A601 in PKP2-ACM. Commercial readiness for KRESLADI and activation of our first Qualified Treatment Centers bring us closer to treating eligible children. Our financial resources and the additional flexibility provided by the Hercules facility support these priorities as we work toward our next clinical and commercial milestones.”
Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals
QXO, Inc. reported third quarter 2026 financial results, including net sales of $4.9 billion and an adjusted EBITDA of $557 million. The results reflect the integration of legacy Beacon, Kodiak, and TopBuild businesses, with management targeting $50 billion in annual revenue within the decade. Additionally, the Board of Directors authorized a new $500 million common stock repurchase program.
“Our organic daily revenue trends improved for the second consecutive quarter despite a soft construction market. Companywide pricing increased 2.2% year over year. We’re prioritizing higher-margin products; in Roofing and Waterproofing, complementary product sales grew 4.2%, and TRI-BUILT reached a record 10.6% of sales. Mechanical insulation distribution revenue grew 16%, supported by strong data center demand.”
Brad Jacobs, chairman and chief executive officer of QXO
“We’re on track to reach $4 billion in adjusted EBITDA by 2030 from the businesses we already own and $50 billion in annual revenue within the decade through organic growth and disciplined acquisitions.”
Brad Jacobs, chairman and chief executive officer of QXO
ARC Group Acquisition I Corp. reported a net income of $1,318,548 for the nine months ended September 30, 2026, primarily driven by $1,822,314 in interest income from its trust account. The company completed its initial public offering in May 2026, resulting in $122,572,314 held in trust and 12,075,000 Class A ordinary shares subject to possible redemption.
NeoVolta reported financial results for the quarter ended September 30, 2026, showing a sequential revenue rebound to $2.8 million driven by its residential third-party ownership (TPO) platform. The company also highlighted a $116 million Master Purchase Agreement for utility-scale products and a strategic 9 GWh battery cell supply collaboration with SK On.
Equillium, Inc. reported a net loss of $4.6 million for the third quarter of 2026, with cash and cash equivalents increasing to $53.3 million as of September 30, 2026, following a private placement. Subsequent to the quarter-end, the company raised an additional $20.0 million in gross proceeds, which management believes will fund operations for at least the next 12 months.
XTI Aerospace reported total assets of $69.9 million as of September 30, 2026, a decrease from $81.2 million at year-end 2025, primarily driven by a reduction in cash and the disposal of its discontinued Inpixon Business. The company's balance sheet reflects significant liabilities including a $24.5 million warrant liability and the introduction of a $5.9 million asset-based revolving line of credit.
Flowers Foods reported third quarter 2026 net sales of $1.169 billion, a 4.7% decrease year-over-year as favorable pricing was offset by lower volumes. Net income fell 63.6% to $14.4 million due to higher logistics costs and marketing investments, leading the company to lower its full-year 2026 financial guidance.
Term
12 weeks
“Our third-quarter results reflect a continued challenging operating environment, driven by pressure on household budgets, evolving consumer behavior and heightened promotional activity, as well as areas where we need to move faster with focused execution.”
Ryals McMullian, chairman and CEO of Flowers Foods
“While it will take time for our initiatives to translate more fully into results, we believe they are putting Flowers on a stronger path forward. We expect the environment to remain challenging in the near term, but we remain confident in the long-term potential of the business.”
Ryals McMullian, chairman and CEO of Flowers Foods
BlossomHill Therapeutics reported third quarter 2026 financial results, ending the period with $224.9 million in cash and cash equivalents. The company aligned with the FDA on a Phase 2 dose for BH-30643 and plans to initiate the pivotal SOLARA-2 trial in Q1 2027 for patients with EGFR C797S-positive NSCLC.
Term
Q3 2026
“We are pleased to have aligned with the FDA on a recommended Phase 2 dose of 50 mg BID based on favorable PK, safety and efficacy data in the Phase 1 portion of the SOLARA trial. We are now preparing to initiate SOLARA-2, a single arm, pivotal Phase 2 trial designed to evaluate BH-30643 in both chemotherapy-naive and chemotherapy-pretreated patients with C797S-positive NSCLC after progression on a third-generation EGFR TKI.”
J. Jean Cui, Ph.D., Founder, President and Chief Executive Officer
Azitra, Inc. reported Q3 2026 financial results and provided updates on its dermatology pipeline, including positive ex vivo results for its ATR-COSF cosmetic program and the advancement of ATR-04 into Cohort 2 of its Phase 1/2 trial. The company highlighted that upcoming clinical data readouts could trigger an additional $5.25 million to $10.5 million in investment from existing institutional investors.
Term
Q3 2026
“During the third quarter and recent weeks, we made substantial progress with our two priority programs, generating encouraging results for ATR-COSF and advancing ATR-04 forward in the clinic while broadening its potential to benefit more patients.”
Francisco Salva, Chief Executive Officer
“The remainder of 2026 has the potential to be a defining period for Azitra as we expect to report initial results from our first in-human cosmetic study of ATR-COSF and topline data from Cohort 1 of our ATR-04 Phase 1/2 trial.”
Crescent Biopharma reported Q3 2026 financial results and provided clinical updates on its lead programs, including the completion of dose escalation for CR-001 in the Phase 1/2 ASCEND trial. The company expects initial monotherapy data for CR-001 in Q1 2027 and highlighted that over 2,000 patients are expected to be dosed across its portfolio by mid-2027.
Counterparty
Kelun-Biotech
“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027.”
Joshua Brumm, chief executive officer of Crescent
“The team’s strong execution has positioned us for several meaningful clinical data readouts in 2027, beginning in the first quarter with monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients, followed by initial standard of care chemotherapy combination data from multiple tumor types.”
KinderCare Learning Companies reported third quarter 2026 revenue of $665.3 million, a 1.7% decrease year-over-year, and a net loss of $85.0 million. The results were impacted by lower enrollment at early childhood education centers and $83.4 million in impairment losses related to market capitalization declines and center closures.
“While third-quarter enrollment at KinderCare Learning Centers fell short of our expectations, recent improvements reinforce our confidence in the operational changes we've made.”
Tom Wyatt, Chairman and Chief Executive Officer
“We know families face tough financial choices, and we’re focused on demonstrating the value of KinderCare’s high-quality education and care across all of our brands.”
Horizon Kinetics Holding Corp reported Q3 2026 financial results, including a net loss of $18.4 million primarily driven by unrealized declines in the fair value of key investment holdings. Despite the quarterly loss, year-to-date net income remains positive at $35.8 million, and the company's Board authorized a new $25 million share repurchase program and declared a $0.13 per share dividend.
Rekor Systems, Inc. reported a decrease in revenue to $10.9 million for the quarter ended September 30, 2026, compared to $14.2 million in the prior year. Despite the revenue decline, the company significantly reduced its net loss to $2.9 million for the quarter, aided by a $3.9 million gain on lease remeasurement and lower overall operating expenses.
Intellicheck, Inc. reported a net income of $1.77 million for the nine months ended September 30, 2026, a significant improvement from a net loss of $279,000 in the prior year period. Total revenues grew to $17.2 million for the nine-month period, and the company maintained a strong liquidity position with $13.17 million in cash and cash equivalents.
Merlin, Inc. reported Q3 2026 revenue of $3.5 million and GAAP net income of $73.8 million, a significant shift from the prior quarter's loss. The company highlighted new contract wins with USSOCOM and USAFRICOM and stated its 2027 plan aims to reduce operating expenses to extend its cash runway into 2029.
Term
Q3 2026
“The new $8.9 million task order with USSOCOM moves our C-130J autonomy program into its integration phase, laying the groundwork for future flight demonstrations and production revenue with SOCOM and ultimately the global C-130J fleet including hundreds of aircraft.”
Matt George, CEO of Merlin
“the goal of our planning process is to ensure that we not only meet the opportunities presented by our current contracts, but also the broader market potential we detailed on last quarter’s call. We believe that it is imperative for Merlin to continue to advance the Merlin Pilot, but it is also imperative that we demonstrate discipline in the investments we make along the way.”